REFERENCES
- AIRTUM, Italian Cancer Figures - Report 2012 Cancer in children and
adolescents Epidemiol Prev 2013; 37(1 Suppl 1): 1-296
- Ferrari A, Brecht IB, Gatta G, et al. Defining and listing very rare
cancers of pediatric age: consensus of the Joint Action on Rare
Cancers (JARC) in cooperation with the European Cooperative Study
Group for Pediatric Rare Tumors (EXPeRT). Eur J Cancer . 2019;
110: 120-126.
- Cordoro KM, Gupta D, Frieden IJ, McCalmont T, Kashani-Sabet M.
Pediatric melanoma: results of a large cohort study and proposal for
modified ABCD detection criteria for children. J Am Acad
Dermatol. 2013; 68: 912–925.
- Ferrari A, Bono A, Baldi M, et al. Does melanoma behave differently in
younger children than in adults? A retrospective study of 33 cases of
childhood melanoma. Pediatrics. 2005; 115 (3): 649-54
- Han D, Zager JS, Han G, et al. The unique clinical characteristics of
melanoma diagnosed in children. Ann SurgOncol . 2012; 19:
3888–3895.
- Spatz A, Ruiter D, Hardmeier T, et al. Melanoma in childhood: an
EORTC–MCG multicenter study on the clinico-pathological aspects.Int J Cancer . 1996; 68: 317–324.
- Massi D, Tomasini C, Senetta R, et al. Atypical Spitz tumors in
patients younger than 18 years. J AmAcad Dermatol. 2015; 72:
37–46.
- Ascierto PA, McArthur GA, Dréno B, et al. Cobimetinib combined with
vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated
efficacy results from a randomised, double-blind, phase 3 trial.Lancet Oncol . 2016; 17:1248–1260.
- Long GV, Stroyakovskiy D, Gogas H, et al. Dabrafenib and trametinib
versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a
multicentre, double-blind, phase 3 randomised controlled trial.Lancet . 2015; 386: 444–451.
- Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Overall survival
with combined nivolumab and ipilimumab in advanced melanoma. N
Engl J Med . 2017; 377: 1345–1356.
- Long GV, Hauschild A, Santinami M, et al. Adjuvant dabrafenib plus
trametinib in stage III BRAF-mutated melanoma. N Engl J Med .
2017; 377: 1813–1823.
- Indini, Brecht IB, Del Vecchio M, Sultan I, Ferrari A. Cutaneous
melanoma in adolescents and young adults. Pediatr Blood Cancer .
2018; 65(11): e27292.
- Ferrari A, Bernasconi A, Sironi G, et al. Where Are Adolescents with
Soft Tissue Sarcomas Treated? An Italian Nationwide Study on Referrals
Based on Hospital Discharge Records. J Adolesc Young Adult
Oncol . 2020; 9 (2): 190-195
- Ferrari A, Bisogno G, Cecchetto G, et al. Cutaneous melanoma in
children and adolescents: the Italian Rare Tumors in Pediatric Age
Project Experience. J Pediatr . 2014; 164: 375–382
- Wouters MW, Michielin O, Bastiaannet E, et al. ECCO essential
requirements for quality cancer care: melanoma. Crit Rev Oncol
Hematol . 2018; 122: 164–178.
- Ascierto PA, McArthur GA, Dréno B, et al. Cobimetinib combined with
vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated
efficacy results from a randomised, double-blind, phase 3 trial.Lancet Oncol . 2016; 17: 1248–1260.
- Chisholm JC, Suvada J, Dunkel IJ, et al. BRIM-P: a phase I,
open-label, multicenter, dose-escalation study of vemurafenib in
pediatric patients with surgically incurable, BRAF mutation-positive
melanoma. Pediatr Blood Cancer . 2018; 65: e26947.
- Geoerger B, Bergeron C, Gore L, et al. Phase II study of ipilimumab in
adolescentswith unresectable stage III or IV malignant melanoma.Eur J Cancer . 2017; 86: 358–363.
- Momper JD, Mulugeta Y, Green DJ, et al. Adolescent dosing and labeling
since the Food andDrug Administration Amendments Act of 2007.JAMA Pediatr. 2007; 167: 926–932.